<DOC>
	<DOCNO>NCT00031954</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat patient stage IC , stage IIB , stage III , stage IV ovarian epithelial , fallopian tube , peritoneal cancer previously treat .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Ovarian Epithelial , Fallopian Tube , Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine tolerability toxicity paclitaxel , carboplatin , gemcitabine patient previously untreated stage IC-IV ovarian epithelial , fallopian tube , peritoneal carcinoma . - Determine response rate patient treat regimen . - Determine time progression overall survival patient treat regimen . OUTLINE : This multicenter study . Patients receive paclitaxel IV 3 hour carboplatin IV 30 minute day 1 gemcitabine IV 30-60 minute day 1 8 . Treatment repeat every 3 week absence disease progression unacceptable toxicity . Patients follow 3 6 month . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage ICIV ovarian epithelial , fallopian tube , peritoneal carcinoma No tumor lowmalignant potential ( borderline tumor ) No symptomatic brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 OR Karnofsky 70100 % Life expectancy : At least 6 month Hematopoietic : WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin great 10 g/dL Hepatic : Bilirubin great 2 time upper limit normal Renal : Glomerular filtration rate least 60 mL/min Cardiovascular : No history congestive heart failure ( New York Heart Association class III IV heart disease ) even medically control No myocardial infarction within past 6 month No history atrial ventricular arrhythmia Neurologic : No history seizure disorder No history CNS disorder No preexisting motor sensory neuropathy symptom grade 2 great Other : No severe concurrent infection No prior hypersensitivity reaction product contain Cremophor EL compound chemically related carboplatin , paclitaxel , gemcitabine No complete bowel obstruction No concurrent severe medical problem would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy No concurrent WBC transfusion Chemotherapy : No prior chemotherapy No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy except replacement therapy steroid antiemetic Radiotherapy : No prior radiotherapy No concurrent radiotherapy Surgery : No 6 week since prior definitive surgery</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage I ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>